{
    "clinical_study": {
        "@rank": "120889", 
        "arm_group": [
            {
                "arm_group_label": "DKN-01 300mg", 
                "arm_group_type": "Experimental", 
                "description": "DKN-01 plus lenalidomide (Revlimid)/dexamethasone"
            }, 
            {
                "arm_group_label": "DKN-01 600mg", 
                "arm_group_type": "Experimental", 
                "description": "DKN-01 plus lenalidomide (Revlimid)/dexamethasone"
            }, 
            {
                "arm_group_label": "Standard of Care", 
                "arm_group_type": "Active Comparator", 
                "description": "Lenalidomide (Revlimid)/dexamethasone"
            }
        ], 
        "brief_summary": {
            "textblock": "A study to evaluate the safety, efficacy and bone changes with combination therapy of\n      intravenous (IV) infused DKN-01 and lenalidomide/dexamethasone, versus lenalidomide and\n      dexamethasone in relapsed or refractory multiple myeloma (MM) patients"
        }, 
        "brief_title": "A Study of DKN-01 and Lenalidomide/Dexamethasone in Patients With Relapsed or Refractory Multiple Myeloma", 
        "completion_date": {
            "#text": "August 2015", 
            "@type": "Anticipated"
        }, 
        "condition": "Multiple Myeloma", 
        "condition_browse": {
            "mesh_term": [
                "Multiple Myeloma", 
                "Neoplasms, Plasma Cell"
            ]
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          -  Relapsed or refractory Multiple Myeloma (MM)\n\n             a. Treated with at least 1 prior regimen for myeloma\n\n               1. Prior treatment with bortezomib (Velcade) is acceptable with a wash-out of 2\n                  weeks\n\n               2. Treatment with prior autologous transplant is permitted\n\n               3. If a transplant is used as consolidation following chemotherapy, without\n                  intervening disease progression, it will be considered 1 line of treatment with\n                  the preceding chemotherapy\n\n          -  Diagnosis of symptomatic MM as defined by the International Myeloma Working Group\n             (IMWG) :\n\n               1. Second line or greater/Refractory/Relapsed, Stage I, Stage II, Stage III\n\n               2. Measureable disease as indicated by monoclonal protein in the serum of greater\n                  than or equal to (\u2265) 1 grams per deciliter (g/dL), involved serum free light\n                  chain assay \u226510 mg/dL (\u2265100 mg/L) provided the serum free light chain ratio is\n                  abnormal; monoclonal light chain in the urine protein electrophoresis of \u2265 200\n                  mg/24 hours, or measurable plasmacytoma\n\n          -  At least 1 osteolytic bone lesion\n\n          -  Disease-free of active second/secondary or prior malignancies for equal to or over 5\n             years with the exception of currently treated basal cell, squamous cell carcinoma of\n             the skin, or carcinoma \"in-situ\" of the cervix or breast\n\n          -  Ambulatory patients greater than or equal to (\u2265) 30 years of age\n\n          -  Performance status of 0 or 1 on the Eastern Cooperative Oncology Group (ECOG) scale\n\n          -  Estimated life expectancy of \u2265 26 weeks\n\n          -  Adequate organ function including:\n\n               1. Hematologic:\n\n                    1. Absolute neutrophil count (ANC) greater than or equal to (\u2265)\n                       1000/microliter\n\n                    2. Platelet (PLT) count \u2265 75,000/microliter\n\n                    3. Hemoglobin (Hgb) \u2265 8.0 g/dL\n\n               2. Acceptable coagulation status:\n\n                    1. Prothrombin time (PT) and partial thromboplastin time (PTT) \u2264 1.2 x the\n                       upper limit of normal (ULN) unless receiving anticoagulation therapy. If\n                       receiving anticoagulation therapy, eligibility will be based upon\n                       International Normalization Ratio (INR)\n\n                    2. International normalized ratio (INR) less than or equal to (\u2264) 1.6 (unless\n                       receiving anticoagulation therapy)\n\n                         -  If receiving warfarin:  INR \u2264 3.0 (and no active bleeding, [i.e., no\n                            bleeding within 14 days prior to first dose of study therapy])\n\n               3. Hepatic:\n\n                    1. Bilirubin \u2264 1.5 x ULN\n\n                    2. Alanine Transaminase (ALT) and Aspartate Transaminase (AST) \u2264 2.5 x ULN (if\n                       liver metastases are present, then \u2264 5 x ULN is allowed)\n\n               4. Renal:\n\n                    1. Calculated creatinine clearance \u2265 45 mL using the Cockcroft and Gault\n                       Method\n\n          -  Women of childbearing potential (WCBP) must have a negative serum or urine pregnancy\n             test within 10 to 14 days and again within 24 hours of starting study drug\n\n               1. WCBP must agree to have pregnancy tests monthly (every 14 days for women with\n                  irregular cycles) while on study drug and 4 weeks after the last dose of study\n                  drug\n\n               2. Men must also agree to use a condom if their partner is of child bearing\n                  potential, even if they have had a successful vasectomy\n\n               3. Males and females with reproductive potential must agree to use medically\n                  approved contraceptive precautions starting 4 weeks prior to initiation of the\n                  therapy and during the trial and for 18 months following the last dose of study\n                  drug\n\n               4. Should a woman become pregnant or suspect she is pregnant while participating in\n                  this study, she should inform her treating physician immediately\n\n          -  Provide written informed consent prior to any study-specific procedures\n\n          -  Are reliable and willing to make themselves available for the duration of the study\n             and are willing to follow study procedures\n\n        Exclusion Criteria:\n\n          -  Received treatment with an investigational drug, which has not received regulatory\n             approval for any indication, within 28 days of study treatment with DKN-01\n\n          -  Received any experimental non-drug therapy (e.g., donor leukocyte/mononuclear cell\n             infusions) within 56 days of entry\n\n          -  Previously treated with an anti-Dickkopf-1 (anti-DKK-1) or antibody therapy, or have\n             had a significant allergy to a known pharmaceutical therapy that, in the opinion of\n             the Investigator, poses an increased risk to the patient\n\n          -  Received radiation therapy, surgery, or chemotherapy within 2 weeks prior to study\n             entry (6 weeks for nitrosoureas or Mitomycin C)\n\n          -  Received bisphosphonates (e.g., etidronate, clodronate, tiludronate, pamidronate,\n             neridronate, olpadronate, alendronate, ibandronate, risedronate, zoledronate) within\n             2 weeks prior to study entry\n\n          -  Symptomatic central nervous system (CNS) malignancy or metastasis.  Patients with\n             treated CNS metastases are eligible provided their disease is radiographically\n             stable, asymptomatic, and they are not currently receiving corticosteroids and/or\n             anticonvulsants.  Screening of asymptomatic patients without a history of CNS\n             metastases is not required\n\n          -  Have a history of major organ transplant (for example:  heart, lungs, liver, and\n             kidney)\n\n          -  Are pregnant or nursing\n\n          -  Known to be human immunodeficiency virus (HIV) positive, have hepatitis B surface\n             antigen (HBSAg), or hepatitis C antibodies (HCAb)\n\n          -  Active, uncontrolled bacterial, viral, or fungal infections, including urinary tract\n             infection, within 7 days of study entry requiring systemic therapy\n\n          -  Serious cardiac condition such as myocardial infarction within the past 6 months,\n             unstable angina, or Class III or IV congestive heart failure as defined by the New\n             York Heart Association (NYHA); have ECG abnormalities including baseline 12-lead ECG\n             with Fridericia-corrected QT interval (QTcF) > 470 msec (female) or > 450 msec\n             (male), a history of congenital long QT syndrome, or any ECG abnormality that, in the\n             opinion of the Investigator, would preclude safe participation in the study\n\n          -  History of osteonecrosis of the hip or have evidence of structural bone abnormalities\n             in the proximal femur on MRI scan that are considered clinically significant or may\n             have an impact on the interpretation of the scan.  Degenerative changes of the hip\n             joint are not exclusionary\n\n          -  Known concomitant disease(s) known to influence calcium metabolism including\n             hyperparathyroidism, hyperthyroidism, Paget's disease of bone, or any other\n             concurrent severe or uncontrolled concomitant medical condition that, in the opinion\n             of the Investigator, would preclude participation in this study\n\n          -  Patients who are currently receiving lithium chloride (LiCl)"
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "N/A", 
            "minimum_age": "30 Years"
        }, 
        "enrollment": {
            "#text": "20", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "October 18, 2012", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT01711671", 
            "org_study_id": "DEK-DKK1-P101", 
            "secondary_id": [
                "DKN-01", 
                "LY2812176"
            ]
        }, 
        "intervention": [
            {
                "arm_group_label": "DKN-01 300mg", 
                "description": "300 mg IV infusion of DKN-01 administered twice per 28 day cycle on Days 1 and 15, plus lenalidomide/dexamethasone", 
                "intervention_name": "DKN-01 300 mg", 
                "intervention_type": "Drug"
            }, 
            {
                "arm_group_label": "DKN-01 600mg", 
                "description": "600 mg IV infusion of DKN-01 administered twice per 28 day cycle on Days 1 and 15, plus lenalidomide/dexamethasone", 
                "intervention_name": "DKN-01 600 mg", 
                "intervention_type": "Drug"
            }, 
            {
                "arm_group_label": "Standard of Care", 
                "description": "Current approved standard of care", 
                "intervention_name": "Standard of Care", 
                "intervention_type": "Drug", 
                "other_name": [
                    "Lenalidomide", 
                    "Revlimid", 
                    "Dexamethasone"
                ]
            }
        ], 
        "intervention_browse": {
            "mesh_term": [
                "Dexamethasone acetate", 
                "Dexamethasone", 
                "Dexamethasone 21-phosphate", 
                "Lenalidomide", 
                "Thalidomide", 
                "BB 1101"
            ]
        }, 
        "is_fda_regulated": "Yes", 
        "is_section_801": "Yes", 
        "lastchanged_date": "March 27, 2014", 
        "location": [
            {
                "facility": {
                    "address": {
                        "city": "Boston", 
                        "country": "United States", 
                        "state": "Massachusetts", 
                        "zip": "02114"
                    }, 
                    "name": "Massachusetts General Hospital"
                }, 
                "investigator": {
                    "last_name": "Andrew Yee, MD", 
                    "role": "Principal Investigator"
                }, 
                "status": "Recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Boston", 
                        "country": "United States", 
                        "state": "Massachusetts", 
                        "zip": "02115"
                    }, 
                    "name": "Dana-Farber Cancer Institute"
                }, 
                "investigator": {
                    "last_name": "Jacob Laubach, MD", 
                    "role": "Principal Investigator"
                }, 
                "status": "Recruiting"
            }
        ], 
        "location_countries": {
            "country": "United States"
        }, 
        "number_of_arms": "3", 
        "official_title": "A Pilot Study of DKN-01 and Lenalidomide (Revlimid\u00ae)/Dexamethasone Versus Lenalidomide/Dexamethasone in Patients With Relapsed or Refractory Multiple Myeloma", 
        "overall_contact": {
            "email": "Dekkun@Choruspharma.com", 
            "last_name": "Dekkun Corporation"
        }, 
        "overall_official": {
            "affiliation": "Dekkun Corporation", 
            "last_name": "Email Dekkun@Choruspharma.com", 
            "role": "Study Director"
        }, 
        "overall_status": "Recruiting", 
        "oversight_info": {
            "authority": "United States: Food and Drug Administration", 
            "has_dmc": "No"
        }, 
        "phase": "Phase 1/Phase 2", 
        "primary_completion_date": {
            "#text": "June 2015", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": [
            {
                "description": "SUV as measured by NaF-PET/CT in both myeloma bone lesions and normal bone", 
                "measure": "Fluorine F18 sodium fluoride positron emission tomography (NaF-PET/CT) standard uptake value (SUV)", 
                "safety_issue": "No", 
                "time_frame": "Pre-study to after 6 months of therapy"
            }, 
            {
                "description": "Ki as measured by NaF-PET/CT in both myeloma bone lesions and normal bone", 
                "measure": "Fluorine F18 sodium fluoride positron emission tomography (NaF-PET/CT) influx constant (Ki)", 
                "safety_issue": "No", 
                "time_frame": "Pre-study to after 6 months of therapy"
            }, 
            {
                "description": "SUV as measured by FDG-PET/CT in both myeloma bone lesions and normal bone", 
                "measure": "F18 fluorodeoxyglucose positron emission tomography (FDG-PET/CT) standard uptake value (SUV)", 
                "safety_issue": "No", 
                "time_frame": "Pre-study to after 6 months of therapy"
            }, 
            {
                "measure": "Number of patients with treatment emergent adverse events", 
                "safety_issue": "Yes", 
                "time_frame": "Baseline to study completion (approximately 7 months)"
            }
        ], 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT01711671"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "secondary_outcome": [
            {
                "measure": "Overall response rate (ORR)", 
                "safety_issue": "No", 
                "time_frame": "Baseline to study completion (approximately 7 months)"
            }, 
            {
                "measure": "Progression free survival (PFS)", 
                "safety_issue": "No", 
                "time_frame": "Baseline to study completion (approximately 7 months)"
            }, 
            {
                "measure": "Duration of response", 
                "safety_issue": "No", 
                "time_frame": "Baseline to study completion (approximately 7 months)"
            }, 
            {
                "measure": "Overall survival", 
                "safety_issue": "No", 
                "time_frame": "Baseline to study completion (approximately 7 months)"
            }, 
            {
                "measure": "Pharmacokinetics: area under the concentration - time curve (AUC) of a single dose of DKN-01", 
                "safety_issue": "No", 
                "time_frame": "Dosing interval of 2 weeks following the first dose in Cycle 1"
            }, 
            {
                "measure": "Pharmacokinetics: maximum plasma concentration (Cmax) of a single dose of DKN-01", 
                "safety_issue": "No", 
                "time_frame": "Dosing interval of 2 weeks following the first dose in Cycle 1"
            }, 
            {
                "measure": "Pharmacokinetics: trough DKN-01 concentrations on Cycle 2 and Cycle 3", 
                "safety_issue": "No", 
                "time_frame": "Cycle 2 Day 1 Pre-dose, Cycle 3 Day 1 Pre-dose"
            }
        ], 
        "source": "Dekkun Corporation", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "Dekkun Corporation", 
                "agency_class": "Other"
            }
        }, 
        "start_date": "May 2013", 
        "study_design": "Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "March 2014"
    }
}